Find your next paid study

M.D. Anderson Cancer CenterNCT02727803

B-cell Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma+2 more

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (NHL)

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, p…

Iksuda Therapeutics Ltd.NCT05365659

~$10 – $8,750

Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+9 more

A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant

This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-sp…

City of Hope Medical CenterNCT07020533

Non Small Cell Lung CancerTriple Negative Breast CancerHodgkin Lymphoma+2 more

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The…

Compass TherapeuticsNCT06150664

~$10 – $8,750

Diffuse Large B-Cell Lymphoma (DLBCL)Hodgkin LymphomaPeripheral T-cell Lymphoma (PTCL)+2 more

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C…

The Methodist Hospital Research InstituteNCT07729397

Non-Hodgkin Lymphoma Refractory/ RelapsedDLBCL - Diffuse Large B Cell LymphomaMantle Cell Lymphoma (MCL)+2 more

A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and eva…

LTZ Therapeutics, Inc.NCT07121946

~$10 – $8,750

Phase 2

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) wo…

Acute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+7 more

Fred Hutchinson Cancer CenterNCT06013423

Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more

A Phase 1/2 Open-Label Study Evaluating the Safety and Efficacy of ST-067 in Combination With CD19-Directed CAR T-Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

This phase I/II trial tests the safety, side effects, and best dose/regimen of ST-067 in combination with CD19-directed chimeric antigen receptor (CAR) T-cell …

Recurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRefractory B Acute Lymphoblastic Leukemia+1 more

A Single-Center, Single-Arm, Phase 1 Pilot Study of Pomalidomide Following CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory CD19+ B-Cell Leukemias and Lymphomas

This phase I trial tests the safety and effectiveness of pomalidomide after CD19 chimeric antigen receptor T-cell (CD19CART) therapy for the treatment of patie…

University of Michigan Rogel Cancer CenterNCT07532525

Phase 2

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.

Large B-cell LymphomaHodgkin Lymphoma

M.D. Anderson Cancer CenterNCT07164469

Phase 2

Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived…

Breast CancerSarcomaGastric Cancer+19 more

University of California, IrvineNCT06580002

Acute Lymphoid LeukemiaAcute Myeloid LeukemiaAcute Undifferentiated Leukemia (AUL)+3 more

A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent or Treat Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation

The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevent…